Sign in

    Andy Chin

    Research Analyst at Wolfe Research

    Andy Chin is an Equity Research Analyst at Wolfe Research, specializing in coverage of the technology hardware and semiconductor sectors, including companies such as Apple Inc., Dell Technologies, and Cisco Systems. He has established a strong performance track record, with his calls being ranked on TipRanks and recognized for generating above-market returns and high accuracy scores. Beginning his career at J.P. Morgan as an associate analyst in 2013, Chin joined Wolfe Research in 2018 and has steadily advanced to his current role through demonstrated analytical rigor and insightful sector coverage. He holds FINRA registration with Series 7, 63, 86, and 87 securities licenses, underlining his professional credentials and regulatory compliance.

    Andy Chin's questions to INSMED (INSM) leadership

    Andy Chin's questions to INSMED (INSM) leadership • Q1 2025

    Question

    An analyst on behalf of Andy Chin asked if the recent patient death in Sarepta's DMD gene therapy trial has influenced Insmed's development strategy for its own gene therapy programs.

    Answer

    CEO William Lewis explained that Insmed's strategy, which uses an intrathecal delivery approach, inherently has safety benefits by reducing the required dose and bypassing the first-pass liver effect. He noted this approach has shown good transduction in preclinical models. He emphasized that the company has taken extra time on its gene therapy programs due to industry-wide safety concerns and has not seen any similar issues in its own work.

    Ask Fintool Equity Research AI